It's no secret that investors flock to biotech stocks for exposure to moonshot returns. For instance, if you invested in Catalyst Pharmaceuticals (NASDAQ: CPRX) around five years ago, you are sitting with a gain of about 239% compared to the market's total return of near 87%.
There's reason to believe the company just might do something similar over the next five years -- but you'll need to tolerate quite a lot of uncertainty along the way. Let's take a look at Catalyst's prospects ahead.
Image source: Getty Images.
For further details see:
Is Now the Time to Buy This Risky Stock With Huge Upside Potential?